Ratto D, Alfaro C, Sipsey J, Glovsky M M, Sharma O P
Department of Pulmonary Medicine, Los Angeles County, University of Southern California Medical Center 90033.
JAMA. 1988;260(4):527-9.
Seventy-seven patients with status asthmaticus were prospectively studied to compare oral with intravenous methylprednisolone. Patients were given methylprednisolone, either 160 or 320 mg orally or 500 or 1000 mg intravenously, daily in equally divided doses. They were randomly assigned to either group on a daily sequential basis. Spirometry was performed within one hour of the initial dose of steroids. The mean presenting forced expiratory volume in 1 s was 26% of the predicted value. Spirometry was then repeated every six hours for the first 24 hours and then every eight to 12 hours until discharge or 72 hours, whichever occurred first. There were no significant differences in the incidence of respiratory failure, forced expiratory volume in 1 s, days of hospitalization, rate of improvement in pulmonary function, or side effects. No patient who went into respiratory failure did so more than three hours after receiving the initial dose of steroids. We conclude that oral methylprednisolone is safe and effective in the treatment of status asthmaticus.
对77例哮喘持续状态患者进行前瞻性研究,以比较口服与静脉注射甲泼尼龙的疗效。患者每日接受甲泼尼龙治疗,口服剂量为160或320毫克,或静脉注射剂量为500或1000毫克,均分为等份剂量给药。他们每天按顺序随机分配到任何一组。在初始剂量的类固醇给药后1小时内进行肺活量测定。初始第1秒用力呼气量平均为预测值的26%。在最初的24小时内,每6小时重复进行一次肺活量测定,然后每8至12小时重复一次,直至出院或72小时(以先发生者为准)。在呼吸衰竭发生率、第1秒用力呼气量、住院天数、肺功能改善率或副作用方面没有显著差异。没有患者在接受初始剂量的类固醇治疗后超过3小时出现呼吸衰竭。我们得出结论,口服甲泼尼龙治疗哮喘持续状态是安全有效的。